Lindforss et al. assessed the prognostic values of circulating KRAS in CRC patients with stagesI-III and found that no significant correlation between relapse of disease and KRAS mutation status in circulating DNA postoperatively on day three [25]. The gene discussed is KRAS; the disease is colorectal carcinoma.